Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated:  12/23/2017
Jefferson County
1939
mi
from 98109
Louisville, KY
Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated: 12/23/2017
Jefferson County
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Electrical Stimulation for Hemiplegic Shoulder Pain
Electrical Stimulation for Hemiplegic Shoulder Pain
Status: Enrolling
Updated:  12/26/2017
MetroHealth Med Ctr
2020
mi
from 98109
Cleveland, OH
Electrical Stimulation for Hemiplegic Shoulder Pain
Electrical Stimulation for Hemiplegic Shoulder Pain
Status: Enrolling
Updated: 12/26/2017
MetroHealth Med Ctr
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated:  12/27/2017
Columbia University Medical Center
2401
mi
from 98109
New York, NY
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated: 12/27/2017
Columbia University Medical Center
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Heart Rate Variability in Response to Metformin Challenge
Heart Rate Variability in Response to Metformin Challenge
Status: Enrolling
Updated:  12/30/2017
Woodinville Psychiatric Associates
11
mi
from 98109
Woodinville, WA
Heart Rate Variability in Response to Metformin Challenge
Heart Rate Variability in Response to Metformin Challenge
Status: Enrolling
Updated: 12/30/2017
Woodinville Psychiatric Associates
11
mi
from 98109
Woodinville, WA
Click here to add this to my saved trials
Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
Imaging [18F]AV-1451 and [18F]AV-45 in Acute and Chronic Traumatic Brain Injury
Status: Enrolling
Updated:  1/2/2018
Icahn School of Medicine at Mount Sinai
mi
from 98109
New York, NY
Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
Imaging [18F]AV-1451 and [18F]AV-45 in Acute and Chronic Traumatic Brain Injury
Status: Enrolling
Updated: 1/2/2018
Icahn School of Medicine at Mount Sinai
mi
from 98109
New York, NY
Click here to add this to my saved trials
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy (TIPN)
Status: Enrolling
Updated:  1/2/2018
Greenville Health System Cancer Institute Center for Integrative Oncology and Survivorship
2229
mi
from 98109
Greenville, SC
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy (TIPN)
Status: Enrolling
Updated: 1/2/2018
Greenville Health System Cancer Institute Center for Integrative Oncology and Survivorship
2229
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
1117
mi
from 98109
Scottsdale, AZ
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
1117
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
1500
mi
from 98109
Kansas City, KA
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
1500
mi
from 98109
Kansas City, KA
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
2400
mi
from 98109
New York, NY
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
704
mi
from 98109
Palo Alto, CA
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
704
mi
from 98109
Palo Alto, CA
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
5239
mi
from 98109
Lyon,
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
5239
mi
from 98109
Lyon,
Click here to add this to my saved trials
Asymmetrical Gait Training After Pediatric Stroke
Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia
Status: Enrolling
Updated:  1/3/2018
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Asymmetrical Gait Training After Pediatric Stroke
Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia
Status: Enrolling
Updated: 1/3/2018
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)
A Proof-of-principle Clinical Study Investigating the Efficacy of a Dissolvable Strip in Providing Rapid Relief From Dentinal Hypersensitivity.
Status: Enrolling
Updated:  1/3/2018
GSK Investigational Site
874
mi
from 98109
Las Vegas, NV
To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)
A Proof-of-principle Clinical Study Investigating the Efficacy of a Dissolvable Strip in Providing Rapid Relief From Dentinal Hypersensitivity.
Status: Enrolling
Updated: 1/3/2018
GSK Investigational Site
874
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Toledo Health Science Campus
1924
mi
from 98109
Toledo, OH
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Toledo Health Science Campus
1924
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
City of Hope National Medical Center
959
mi
from 98109
Duarte, CA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
City of Hope National Medical Center
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
UCLA Medical School
979
mi
from 98109
Los Angeles, CA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
UCLA Medical School
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Kentucky
2005
mi
from 98109
Lexington, KY
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Kentucky
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Boston University School of Medicine
2485
mi
from 98109
Boston, MA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Boston University School of Medicine
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Washington University School of Medicine
1718
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Duke University
2341
mi
from 98109
Durham, NC
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Duke University
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Texas- Houston Medical School
1892
mi
from 98109
Houston, TX
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Texas- Houston Medical School
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Fred Hutchinson Cancer Research Center (FHCRC)
0
mi
from 98109
Seattle, WA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Fred Hutchinson Cancer Research Center (FHCRC)
0
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Calgary
mi
from 98109
Calgary,
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Calgary
mi
from 98109
Calgary,
Click here to add this to my saved trials
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Status: Enrolling
Updated:  1/5/2018
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Status: Enrolling
Updated: 1/5/2018
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Harmonex Neuroscience Research
2242
mi
from 98109
Dothan, AL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Harmonex Neuroscience Research
2242
mi
from 98109
Dothan, AL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
ProScience Research Group
964
mi
from 98109
Culver City, CA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
ProScience Research Group
964
mi
from 98109
Culver City, CA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
MCB Clinical Research Centers
1067
mi
from 98109
Colorado Springs, CO
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
MCB Clinical Research Centers
1067
mi
from 98109
Colorado Springs, CO
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Sarkis Clinical Trials
2450
mi
from 98109
Gainesville, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Sarkis Clinical Trials
2450
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Indago Research & Health Center, Inc.
2722
mi
from 98109
Hialeah, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Indago Research & Health Center, Inc.
2722
mi
from 98109
Hialeah, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Clinical Neuroscience Solutions, Inc.
2457
mi
from 98109
Jacksonville, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Clinical Neuroscience Solutions, Inc.
2457
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Florida Clinical Research Center LLC
2543
mi
from 98109
Maitland, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Florida Clinical Research Center LLC
2543
mi
from 98109
Maitland, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Clinical Neuroscience Solutions, Inc
2549
mi
from 98109
Orlando, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Clinical Neuroscience Solutions, Inc
2549
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Miami Research Associates
2730
mi
from 98109
South Miami, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Miami Research Associates
2730
mi
from 98109
South Miami, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Atlanta Center for Medical Research
2178
mi
from 98109
Atlanta, GA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Atlanta Center for Medical Research
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
iResearch Atlanta LLC
2182
mi
from 98109
Decatur, GA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
iResearch Atlanta LLC
2182
mi
from 98109
Decatur, GA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Capstone Clinical Research
1706
mi
from 98109
Libertyville, IL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Capstone Clinical Research
1706
mi
from 98109
Libertyville, IL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Baber Research Group
1709
mi
from 98109
Naperville, IL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Baber Research Group
1709
mi
from 98109
Naperville, IL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Goldpoint Clinical Research
1862
mi
from 98109
Indianapolis, IN
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Goldpoint Clinical Research
1862
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Pedia Research, LLC
1875
mi
from 98109
Newburgh, IN
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Pedia Research, LLC
1875
mi
from 98109
Newburgh, IN
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Psychiatric Associates
1507
mi
from 98109
Overland Park, KA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Psychiatric Associates
1507
mi
from 98109
Overland Park, KA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Pedia Research LLC
1892
mi
from 98109
Owensboro, KY
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Pedia Research LLC
1892
mi
from 98109
Owensboro, KY
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Neurobehavioral Medicine Group, Clinical Trials Division
1916
mi
from 98109
Bloomfield Hills, MI
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Neurobehavioral Medicine Group, Clinical Trials Division
1916
mi
from 98109
Bloomfield Hills, MI
Click here to add this to my saved trials